Skip to main content

Vigo is pleased to have been appointed by Acercor Therapeutics as strategic communications adviser to enhance their corporate reputation and investor communications. AIM-listed Arecor is a biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic disease.

Author

Vigo Consulting
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.